SCHEMBL1807255

SCHEMBL1807255

CC(=O)N(C[C@@H]1CN(Cc2ccc(F)c(F)c2)CCO1)Sc1nc(-c2ccc(C(N)=O)cc2)cs1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 1/20 0.40
DRD4 P21917 5/20 0.39
GRM2 Q14416 7/20 0.38
KCNH2 Q12809 2/20 0.38
SIGMAR1 Q99720 3/20 0.37
DRD2 P14416 1/20 0.36
HTR2A P28223 1/20 0.36
NR1I2 O75469 1/20 0.36
FYN P06241 1/20 0.34
RAB9A P51151 3/20 0.34
LCK P06239 1/20 0.34
CSF1R P07333 1/20 0.34
LMNA P02545 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
KDM4E B2RXH2 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PIM1 P11309 1/20 0.34
PIM3 Q86V86 1/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1807518 0.94 DRD4 (0.41) DRD4GRM2KCNH2SIGMAR1DRD2
SCHEMBL1810623 0.91 CCR3 (0.51) CCR3DRD4GRM2KCNH2DRD2
SCHEMBL1807192 0.89 DRD4 (0.43) DRD4GRM2KCNH2SIGMAR1NR1I2
SCHEMBL1807782 0.85 DRD4 (0.43) DRD4GRM2KCNH2SIGMAR1RAB9A
SCHEMBL1807203 0.85 DRD4 (0.45) DRD4GRM2KCNH2SIGMAR1RAB9A
SCHEMBL1806562 0.84 CCR3 (0.42) CCR3DRD4DRD2HTR2ARAB9A
SCHEMBL1807441 0.83 DRD4 (0.44) CCR3DRD4GRM2KCNH2SIGMAR1
SCHEMBL1809878 0.83 DRD4 (0.45) DRD4SIGMAR1RAB9AKDM4E
SCHEMBL1812609 0.83 DRD4 (0.39) CCR3DRD4GRM2KCNH2SIGMAR1
SCHEMBL1807254 0.81 CCR3 (0.48) CCR3DRD4GRM2KCNH2DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1801108-B9 MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS MITSUBISHI TANABE PHARMA CORP (JP) 2013-11-20 EP disclosed
EP-1801108-B1 MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS MITSUBISHI TANABE PHARMA CORP (JP) 2012-11-14 EP disclosed
US-7935700-B2 Morpholine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-03 US disclosed
US-20070265257-A1 Morpholine Compound MITSUBISHI PHARMA CORPORATION (JP) 2007-11-15 US disclosed
EP-1801108-A1 MORPHOLINE COMPOUND Mitsubishi Pharma Corporation (JP) 2007-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265257-A1 Morpholine Compound CCR3, CCR1, CCR4 CCR3 1/4885DRD4 768/4885GRM2 1117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.